Open access · OA
via OpenAlex
Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy
Hirofumi Hamada, Masayoshi Kobune, Kiminori Nakamura, Yutaka Kawano, Kazunori Kato, Osamu Honmou, Kiyohiro Houkin, Takuya Matsunaga, Yoshiro Niitsu
Cancer Science · 2005 · ▲ 209 citations
Abstract
We developed human mesenchymal stem cell (MSC) lines that could differentiate into various tissue cells including bone, neural cells, bone marrow (BM) stromal cells supporting the growth of hematopoietic stem cell (HSC), and so-called 'tumor stromal cells' mixing with tumor cells. We investigated the applicability of MSC as therapeutic cell transplanting reagents (cytoreagents). Telomerized human BM derived stromal cells exhibited a prolonged lifespan and supported the growth of hematopoietic clonogenic cells. The gene transfer of Indian hedgehog (Ihh) remarkably enhanced the HSC expansion supported by the human BM stromal cells. Gene-modified MSC are useful as therapeutic tools for brain tissue damage (e.g. brain infarction) and malignant brain neoplasms. MSC transplantation protected the brain tissue from acute ischemic damage in the midcerebral artery occlusion (MCAO) animal model. Brain-derived neurotrophic factor (BDNF)-gene transduction further enhanced the protective efficacy against the ischemic damage. MSC possessed excellent migratory ability and exerted inhibitory effects on the proliferation of glioma cells. Gene-modification of MSC with therapeutic cytokines clearly augmented the antitumor effect and prolonged the survival of tumor-bearing animals. Gene therapy employing MSC as a tissue-protecting and targeting cytoreagent would be a promising approach.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/j.1349-7006.2005.00032.x
- Canonical
- link ↗
- Fetched
- 2026-09-21 MST
Cite this
APA
Hamada, H., Kobune, M., Nakamura, K., Kawano, Y., Kato, K., Honmou, O., Houkin, K., Matsunaga, T., & Niitsu, Y. (2005). Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. <em>Cancer Science</em>. https://doi.org/10.1111/j.1349-7006.2005.00032.x
Vancouver
Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Science. 2005. doi:10.1111/j.1349-7006.2005.00032.x.
BibTeX
@article{hirofumi2005Mesenc,
title = {Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy},
author = {Hirofumi Hamada and Masayoshi Kobune and Kiminori Nakamura and Yutaka Kawano and Kazunori Kato and Osamu Honmou and Kiyohiro Houkin and Takuya Matsunaga and Yoshiro Niitsu},
journal = {Cancer Science},
year = {2005},
doi = {10.1111/j.1349-7006.2005.00032.x},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Circulation Research 2011
Open access · OA
Mesenchymal Stem Cells: Biology, Pathophysiology, Translational Findings, and Therapeutic Implications for Cardiac Disease
Expert Opinion on Biological Therapy 2023
Preprint · OA
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells
BMC Medicine 2015
Open access · CC-BY
Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies
Biomedicine & Pharmacotherapy 2022
Open access · CC-BY
CRISPR/Cas9-engineered mesenchymal stromal/stem cells and their extracellular vesicles: A new approach to overcoming cell therapy limitations
Rejuvenation Research 2012
Preprint · OA
Tissue Inhibitor of Matrix Metalloproteinase-3 or Vascular Endothelial Growth Factor Transfection of Aged Human Mesenchymal Stem Cells Enhances Cell Therapy after Myocardial Infarction
2021
Preprint · OA